Skip to main content
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. — Investor Relations & Filings

Ticker · LENZ ISIN · US38870X1046 US Manufacturing
Open in API
Filings indexed 329 across all filing types
Latest filing 2022-06-22 Director's Dealing
Country US United States of America
Listing US LENZ

About LENZ Therapeutics, Inc.

https://lenz-tx.com/

LENZ Therapeutics, Inc. is a late-stage pharmaceutical company focused on developing and commercializing ophthalmic therapies to improve vision. Its primary product is VIZZ™ (aceclidine ophthalmic solution) 1.44%, an FDA-approved eye drop for the treatment of presbyopia, the age-related loss of near vision. VIZZ is the first aceclidine-based therapy for this condition, which affects an estimated 1.8 billion people globally. The product is designed to restore near vision, providing a pharmaceutical alternative to reading glasses for a broad patient population.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-06-22 English
FORM 4 SUBMISSION
Director's Dealing
2022-06-22 English
FORM 4 SUBMISSION
Director's Dealing
2022-06-22 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a press release about preclinical gene replacement data presented at a conference, attached as an exhibit. There are no detailed financial statements or comprehensive financial analysis included. The document length is 3077 characters, which is relatively short and primarily serves as an announcement of an event and a press release. This fits the profile of a Regulatory Filing (RNS) rather than a full financial report or earnings release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-05-16 English
10-Q
Interim / Quarterly Report Q1 2022
2022-05-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 12, 2022, reporting the financial results for the quarter ended March 31, 2022. It includes a press release announcing the financial results but does not contain the full financial statements or detailed financial analysis itself. The document length is 3611 characters, which is relatively short and mainly serves to announce the earnings release. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER).
2022-05-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.